Table 5. Overall pooled prevalence of mental and neurological manifestations for individual drugs.
| Antimalarial
drug |
Estimated
percentage pooled median prevalence with corresponding 95%CI |
Median overall
prevalence in prophylaxis studies (95%CI) |
Median overall
prevalence in malaria studies c(95%CI) |
|---|---|---|---|
| Amodiaquine | 42.7 (36.3–49.2) | - | 42.7 (36.3–49.2) |
| Artemether | 1.1 (0.9–1.4) | 2.4 (0.5–4.3) | 1.1 (0.9–1.4) |
| Artesunate | 1.1 (0.9–1.3) | 1.9 (0.2–4.0) | 1.1 (0.8–1.3) |
| Atovaquone | 8.0 (7.3–8.7) | 8.7 (8.0–9.4) | 8.0 (7.3–8.7) |
| Chloroquine | 7.1 (7.0–7.2) | 7.1 (7.0–7.2) | 4.9 (1.9–7.8) |
| Dapsone | 0.7 (0.6–1.9) | 0.7 (0.6–1.9) | - |
| Doxycycline | 1.6 (1.5–1.8) | 1.6 (1.5–1.8) | - |
| Lumefantrine | 29.5 (27.0–32.0) | - | 29.5 (27.0–32.0) |
| Mefloquine | 1.9 (1.6–2.1) | 25.0 (23.8–26.3) | 1.0 (0.7–1.2) |
| Minocycline | 48.3 (35.7–61.0) | 48.3 (35.7–61.0) | - |
| Primaquine | 0.7 (0.6–1.9) | 0.6 (0.6–1.9) | - |
| Proguanil | 7.3 (7.2–7.4) | 7.3 (7.2–7.4) | - |
| Pyrimethamine | 20.8 (20.6–21.0) | 22.3 (22.0–22.5) | 0.6 (0.2–1.4) |
| Quinidine | 16.1 (3.2–29.1) | 16.1 (3.2–29.1) | - |
| Quinine | 1.7 (0.5–2.9) | 0.7 (0.6–1.9) | 9.3 (5.9–12.7) |
| Sulfadoxine | 6.0 (5.2–6.8) | 55.0 (52.6–57.4) | 0.6 (0.1–1.4) |
- No observations